Navigation Links
QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy

Primary Endpoints Met; Data Demonstrate MoxDuo(TM) IR Provides Better Tolerability Than Morphine and Oxycodone Alone

SYDNEY, Australia and BEDMINSTER, N.J., April 20 /PRNewswire-FirstCall/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the successful completion of a Phase 3 program pilot study comparing the efficacy and safety profile of MoxDuo(TM) IR against component doses of morphine and oxycodone. Results demonstrated that MoxDuo(TM) IR reduces pain significantly more than its component doses; further, when compared to equianalgesic doses of morphine and oxycodone, MoxDuo(TM) IR produced fewer and less intense side effects. These results confirm 12mg/8mg morphine plus oxycodone combination as the preferred dose for optimal efficacy and tolerability as well as provide sample size guidance for the upcoming Phase 3 Combination Rule study required for NDA submission in 2010.

"Having achieved statistical significance in measures of decreased pain intensity with MoxDuo(TM) IR compared to its component doses, this pilot study exceeded expectations. Completed ahead of schedule and on budget, trial data clearly demonstrated the clinical and commercial value of our patented Dual-Opioid(TM), with the potential to give patients greater tolerability than morphine or oxycodone alone," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "From these data, we are confident that our upcoming Phase 3 Combination Rule study will prove successful."

In this randomized, double blind study of 197 patients at 6 US clinical research sites, MoxDuo(TM) IR was compared to morphine and oxycodone in managing acute pain during the first 24 hours following a scheduled surgical procedure (bunionectomy). When postoperative pain reached a measure of at least "4" (moderate pain, with 10 being the most severe) on the Numerical Pain Rating Scale, patients received either MoxDuo(TM) IR, morphine or oxycodone every 6 hours for 48 hours. The study's primary clinical endpoint was changes in the pain intensity scores from baseline for MoxDuo(TM) IR versus component doses of morphine and oxycodone alone. Secondary endpoints included: (1) pain relief and global assessment of effect; and (2) safety as measured by the incidence and intensity of opioid-related adverse events.

In terms of reduced pain intensity scores and other related measures, the analgesic effects of 12mg/8mg MoxDuo(TM) IR were 80-100% greater than the components, morphine or oxycodone. The 6mg/4mg MoxDuo(TM) IR dose also showed similar improvements when compared to its individual components.

Significantly, the frequency of moderate to severe adverse events (including nausea, vomiting, constipation, dizziness, etc.) was 25% to 75% lower among patients on MoxDuo(TM) IR compared to those receiving equi-analgesic doses of morphine or oxycodone alone. Furthermore, patients receiving morphine or oxycodone alone were two to four times more likely to prematurely discontinue dosing than those on MoxDuo(TM) IR.

"These data indicate that MoxDuo(TM) IR has the potential to provide superior pain relief with a lower frequency and severity of side effects when compared to either morphine or oxycodone," said Holaday. "The improved tolerability profile should enable pain practitioners to prescribe higher doses of MoxDuo(TM) IR to achieve better pain relief with fewer side effects than morphine or oxycodone alone."

Additional studies evaluating MoxDuo(TM) IR versus Percocet(R) in patients with joint replacement surgery are underway, with results expected in Q3 of 2009.

Forward Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of QRxPharma as of the date of this release. These forward-looking statements are not guarantees for future performance. Actual results could differ materially from those currently anticipated to due to a number of factors including risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization of the Company's proposed products.

About QRxPharma

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) is a clinical-stage specialty pharmaceutical company with a core focus on the development and commercialization of new treatments for pain management and central nervous system (CNS) disorders. Based on a development strategy which focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. The Company intends to directly commercialize its products in the US and seek strategic partnerships abroad. QRxPharma's lead compound, MoxDuo(TM) IR, successfully completed a Phase 3 study and met primary and secondary endpoints. The Company's preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease and venomics. For more information:

SOURCE QRxPharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
4. Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs
5. MicroPhage Successfully Completes Beta Trial for Rapid MRSA Test
6. Quigley Anti-Viral Compound QR448(a) Successfully Prevents Transmission of Infectious Bronchitis in Chickens
7. Hope for Progeria - Successfully Validated on Mice, a Treatment Could Soon be Tested on Children
8. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
9. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
10. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
11. New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol
Post Your Comments:
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia ... the company,s second affiliate in Latin America . ... ... Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... On ... as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle ... honor of the city’s history as home to some of the world’s leading providers ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
Breaking Medicine News(10 mins):